New York, New York 10065


The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.


Inclusion Criteria: - Histologic diagnosis classical Hodgkin's lymphoma. - Primary refractory or relapsed disease proven by excisional or core needle biopsy. - Relapse or refractory disease following 1 line of multi-agent chemotherapy. - Be willing and able to provide written informed consent/assent for the trial. - Be ≥ 10 years of age on day of signing informed consent. - Have measurable disease based on RECIL26 - Have a performance status of 0 or 1 on the ECOG Performance Scale. - Demonstrate adequate organ function as defined in table below. - Absolute neutrophil count (ANC) ≥1000 /mcL - Platelets ≥50,000 / mcL - Hemoglobin ≥8 g/dL - Serum creatinine OR ≤1.5 X upper limit of normal (ULN) OR - Measured or calculateda creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≥60 mL/min for subject with creatinine levels > 1.5 X institutional ULN - Serum total bilirubin ≤ 1.5 X ULN OR ≤ 3 X ULN for subjects with liver metastases - AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases - Hemoglobin-adjusted diffusing capacity for carbon monoxide ≥50% - Ejection fraction ≥45% - Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. - Female subjects of childbearing potential must be willing to use an adequate method of contraception - Male subjects of childbearing potential must agree to use an adequate method of contraception. Exclusion Criteria: - Received more than 1 prior treatment (combined modality therapy represents 1 treatment) for Hodgkin Lymphoma - Known pregnancy or breast-feeding. - Medical illness unrelated to Hodgkin's Lymphoma, which, in the opinion of the attending physician and/or principal investigator, makes participation in this study inappropriate. - Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. - Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. - Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. - Has known active HIV, Hepatitis B (e.g., Hepatitis B PCR positive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected). - Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. - Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. - Has an active infection requiring systemic therapy. - Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Subjects who have had an allogeneic hematopoietic transplant greater than 5 years ago are eligible as long as there are no symptoms of GVHD.)



Primary Contact:

Principal Investigator
Alison Moskowitz, MD
Memorial Sloan Kettering Cancer Center

Alison Moskowitz, MD
Phone: 212-639-4839

Backup Contact:

Heiko Schoder, MD
Phone: 212-639-2079

Location Contact:

New York, New York 10065
United States

Alison Moskowitz, MD
Phone: 212-639-4839

Site Status: Recruiting

Data Source:

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.